Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Open Access
- 1 September 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (9), 1077-1083
- https://doi.org/10.1158/1940-6207.capr-10-0186
Abstract
The biguanide metformin is widely used for treating diabetes mellitus. We previously showed the chemopreventive effect of metformin in two rodent models of colorectal carcinogenesis. However, besides epidemiologic studies, little is known about the effects of metformin on human colorectal carcinogenesis. The objective of this pilot study was to evaluate the chemopreventive effect of metformin on rectal aberrant crypt foci (ACF), which are an endoscopic surrogate marker of colorectal cancer. We prospectively randomized 26 nondiabetic patients with ACF to treatment with metformin (250 mg/d, n = 12) or no treatment (control, n = 14); 23 patients were evaluable for end point analyses (9 metformin and 14 control); the two groups were similar in ACF number and other baseline clinical characteristics. Magnifying colonoscopy determined the number of rectal ACF in each patient at baseline and after 1 month in a blinded fashion (as were all laboratory end point analyses). We also examined proliferative activity in colonic epithelium (via proliferating cell nuclear antigen labeling index) and apoptotic activity (via terminal deoxynucleotidyl transferase dUTP nick-end labeling). At 1 month, the metformin group had a significant decrease in the mean number of ACF per patient (8.78 ± 6.45 before treatment versus 5.11 ± 4.99 at 1 month, P = 0.007), whereas the mean ACF number did not change significantly in the control group (7.23 ± 6.65 versus 7.56 ± 6.75, P = 0.609). The proliferating cell nuclear antigen index was significantly decreased and the apoptotic cell index remained unaltered in normal rectal epithelium in metformin patients. This first reported trial of metformin for inhibiting colorectal carcinogenesis in humans provides preliminary evidence that metformin suppresses colonic epithelial proliferation and rectal ACF formation in humans, suggesting its promise for the chemoprevention of colorectal cancer. Cancer Prev Res; 3(9); 1077–83. ©2010 AACR.Keywords
Other Versions
This publication has 31 references indexed in Scilit:
- Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinaseMolecular Carcinogenesis, 2010
- Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthaseEndocrine-Related Cancer, 2010
- New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 2009
- Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or HypoglycemiaDiabetes Care, 2008
- Adiponectin suppresses colorectal carcinogenesis under the high-fat diet conditionGut, 2008
- Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind TrialCancer Prevention Research, 2008
- Chemoprevention of Colorectal CancerDigestion, 2007
- Influence of obesity on the risk of developing colon cancerGut, 2006
- Growing roles for the mTOR pathwayCurrent Opinion in Cell Biology, 2005
- Aberrant crypts in human colonic mucosa: Putative preneoplastic lesionsJournal of Cellular Biochemistry, 1992